Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients
Crossref DOI link: https://doi.org/10.1186/s13045-016-0297-7
Published Online: 2016-08-11
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Zhang, Pin
Tong, Zhongsheng
Tian, Fuguo
Wang, Yongsheng
Yang, Junlan
Li, Weilian
Di, Lijun
Liu, Wei
Tang, Li
Qiu, Rongguo
Xu, Binghe
Funding for this research was provided by:
Beijing Biostar Tech, Ltd, Beijing, China